Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience

Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience

Immune-checkpoint inhibitors (ICIs) have been proven to have great efficacy in non-small cell lung cancer (NSCLC) as single agents or in combination therapy, being capable to induce deep and durable remission. However, severe adverse events may occur and about 40% of patients do not benefit from the...

Full description

Bibliographic Details
Main Authors: Lavinia Monaco, Maria Gemelli, Irene Gotuzzo, Matteo Bauckneht, Cinzia Crivellaro, Carlo Genova, Diego Cortinovis, Lodovica Zullo, Luca Carlofrancesco Ammoni, Davide Paolo Bernasconi, Giovanni Rossi, Silvia Morbelli, Luca Guerra
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
immunotherapy
NSCLC
PET/CT
response to therapy
metabolic tumor volume
quantification
Online Access:https://www.mdpi.com/2072-6694/13/7/1634

Internet

https://www.mdpi.com/2072-6694/13/7/1634

Similar Items